ly3022855
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2015 (NCT02265536)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CSF1R inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ly3022855
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03101254 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2017 | Eli Lilly, Harvard University |
| NCT02718911 | Phase 1 | Jun 1, 2016 | AstraZeneca, Eli Lilly |
| NCT02265536 | Phase 1 | May 1, 2015 | Eli Lilly |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 2 | 2 | 2015 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1